Mon, Oct 20, 2014, 4:25 AM EDT - U.S. Markets open in 5 hrs 5 mins

Recent

% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

  • simp08801 simp08801 May 6, 2013 2:47 PM Flag

    this is just the opinion of rice-aroni

    rice-aroni has a theory for conspiracy luvers as to why why why, and then more why, GSK is failing to deliver its dystrophin data until October 2013

    let us all agree that it is total lunacy, cubed, for GSK to continue to say it is analyzing dystrophin data it has had for well over a year!

    its embarrassing for GSK to be saying this, as it cannot be THE reason

    so what IS the REASON?

    before we answer that question, let us all agree that dystrophin is NOT produced via the placebo effect

    and let us all agree that after around age 8, boys do not show any walking improvement via placebo effect

    and let us all agree that the GSK drug has shown varying levels of clinical efficacy

    SO, by definition, the GSK drug must be producing dystrophin

    SO WHY IS GSK HOLDING THE DATA?

    the answer is SIMPle ...

    GSK's release of the dystrophin data is perfectly supportive of the very thing the FDA asked Srpt to provide supplemental info on ... namely, that production of dystrophin is correlated to clinical efficacy

    GSK has produced dystrophin on a 50+ boy, multiple site (hi shorts!) trial, which dystrophin production has led to varying degrees of clinical efficacy

    THERE IS NO WAY ON EARTH GSK WILL RELEASE THIS DATA AND HAVE IT BE USED TO SUPPORT SRPT'S AA APP CHANCES

    PERIOD

    END OF STORY

    rice-aroni is accepting large cash gifts for this information

    all gifts are to be delivered to Bud, rice-aroni's promotional agent

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • ,,now that's a post.... the fda can see thru this....they are not going to commit a crime for GSK's eyes.

    • There seem to be 2 reasons for the delay- either there is a problem and they are waiting for broader phase 3 results or as you say the data is good or at least OK and would be used against them. I am very interested to see if the functionality of any dystrophin produced is stable in the GSK intermitant dosing. Both theories above support AA. If dystrophin is being produced than it supports the concept and if it is not then SRPT is the only game in town.

      Sentiment: Strong Buy

      • 2 Replies to dylacha
      • I believe that scientifically speaking, it is a 100% certainty that GSK produced some kind of functional dystrophin

        fi this is not the case, then the only other answer is that GSK boys had functional improvement, all based on placebo effect

        I think not

        seems to me that the dystrophin data shows dystrophin restoration, which would then be characterized as a likely reason for the clinical benefit that was measured

        GSK DOES NOT WANT THIS ON THE SRPT NATURAL HISTORY LIST

        THE DATA COMES FROM A MUCH LARGER, MULTIPLE SITE TRIAL

        GSK surely knows this would be supportive of the Srpt data submission

        now there are all kinds of safety issues with GSK, but that has nothing to do with the fact that the GSK drug must be producing some kind of functional dystrophin

      • dylacha,
        nice to see you're still around. All the best

        jrrt1

        Sentiment: Hold

 
SRPT
22.22-0.08(-0.36%)Oct 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Netflix, Inc.
NasdaqGSFri, Oct 17, 2014 4:00 PM EDT
Amicus Therapeutics, Inc.
NasdaqGMFri, Oct 17, 2014 4:00 PM EDT